How much funding has Aptamino raised?

Aptamino has raised $8.0M in total funding, most recently a Seed round.

Who are Aptamino's investors?

Aptamino's investors include Freestyle Capital, Modi Ventures, Spacecadet Ventures, The Engine, University of Toronto.

Where is Aptamino headquartered?

Aptamino is headquartered in Cambridge, Massachusetts, United States.

Aptamino

The Oral Antibody Company

Cambridge, United States · $8.0M raised

Biotech

Headquarters: Cambridge, Massachusetts
Employees: 1–10
Business Model: B2B

Total Funding: $8.0M
Last Round: $8.0M SeedApr 2026
Rounds: 1

About

Aptamino is a seed-stage biotechnology company developing oral antibody therapeutics. Operating in stealth mode, the company is focused on engineering antibody structures that can be delivered orally rather than via injection, addressing a significant challenge in protein drug delivery. Aptamino is headquartered in Cambridge, Massachusetts, and has filed patents on coiled coil immunoglobulin fusion proteins and antibody-IL2 engrafted proteins for cancer treatment applications. The company is in early-stage research and has been recruiting protein science researchers to build out its discovery capabilities.

Summary

Aptamino is a Biotech company based in Cambridge, United States. It has raised $8.0M in total across 1 round, most recently a $8.0M Seed round in Apr 2026. Investors include Freestyle Capital, Modi Ventures and Spacecadet Ventures.